ESMO20 YO for YO: highlights on metastatic NSCLC-Keynote 024 update.
作者信息
Mariamidze E, Mezquita L
机构信息
Research Institute of Clinical Medicine, Todua Clinic-Department of Oncology and Hematology, Tbilisi, Georgia.
Thoracic Oncology Group, Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain; Laboratory of Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain.
出版信息
ESMO Open. 2021 Feb;6(1):100022. doi: 10.1016/j.esmoop.2020.100022. Epub 2021 Jan 4.
Abstract
摘要
相似文献
1
ESMO20 YO for YO: highlights on metastatic NSCLC-Keynote 024 update.ESMO 20年随访20年：转移性非小细胞肺癌的要点——KEYNOTE-024更新
ESMO Open. 2021 Feb;6(1):100022. doi: 10.1016/j.esmoop.2020.100022. Epub 2021 Jan 4.
2
ESMO20 YO for YO: highlights on oncogene-addicted NSCLC.针对年轻患者的欧洲肿瘤内科学会（ESMO）20 年：成瘾性致癌基因非小细胞肺癌的亮点
ESMO Open. 2021 Feb;6(1):100026. doi: 10.1016/j.esmoop.2020.100026. Epub 2020 Dec 31.
3
ESMO20 YO for YO: highlights on metastatic renal cell carcinoma-the CheckMate-9ER trial.ESMO面向青年肿瘤学家的20年回顾：转移性肾细胞癌的亮点——CheckMate-9ER试验
ESMO Open. 2021 Feb;6(1):100025. doi: 10.1016/j.esmoop.2020.100025. Epub 2021 Jan 4.
4
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.帕博利珠单抗单药治疗 PD-L1 阳性晚期非小细胞肺癌老年患者的安全性和有效性：来自 KEYNOTE-010、KEYNOTE-024 和 KEYNOTE-042 研究的汇总分析。
Lung Cancer. 2019 Sep;135:188-195. doi: 10.1016/j.lungcan.2019.07.004. Epub 2019 Jul 8.
5
Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study.帕博利珠单抗对比化疗用于未经治疗的、PD-L1 阳性的局部晚期或转移性非小细胞肺癌中国患者的随机临床研究：KEYNOTE-042 中国研究。
Int J Cancer. 2021 May 1;148(9):2313-2320. doi: 10.1002/ijc.33399. Epub 2020 Dec 9.
6
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.帕博利珠单抗联合化疗对比单纯化疗用于无肿瘤 PD-L1 表达的晚期非小细胞肺癌患者：3 项随机对照研究的汇总分析。
Cancer. 2020 Nov 15;126(22):4867-4877. doi: 10.1002/cncr.33142. Epub 2020 Sep 11.
7
Pembrolizumab Shows Promise for NSCLC.帕博利珠单抗有望用于 NSCLC。
Cancer Discov. 2015 Jun;5(6):572. doi: 10.1158/2159-8290.CD-NB2015-057. Epub 2015 Apr 20.
8
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.既往放疗与帕博利珠单抗治疗非小细胞肺癌的临床活性及毒性：KEYNOTE-001 1期试验的二次分析
Lancet Oncol. 2017 Jul;18(7):895-903. doi: 10.1016/S1470-2045(17)30380-7. Epub 2017 May 24.
9
Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.帕博利珠单抗对比标准治疗化疗用于 PD-L1 阳性（>50%）转移性鳞状和非鳞状非小细胞肺癌一线治疗的成本效果分析。在法国。
Lung Cancer. 2019 Jan;127:44-52. doi: 10.1016/j.lungcan.2018.11.008. Epub 2018 Nov 23.
10
Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study.帕博利珠单抗联合培美曲塞-铂类用于转移性非鳞状非小细胞肺癌：KEYNOTE-189 日本研究。
Cancer Sci. 2021 Aug;112(8):3255-3265. doi: 10.1111/cas.14980. Epub 2021 Jun 15.
引用本文的文献
1
Pembrolizumab in the treatment of non-small cell lung cancer-experiences from clinical practice.帕博利珠单抗治疗非小细胞肺癌——临床实践经验
Front Med (Lausanne). 2025 Sep 1;12:1635626. doi: 10.3389/fmed.2025.1635626. eCollection 2025.
2
The Efficacy of PD-1/PD-L1 Inhibitors in Patients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study.PD-1/PD-L1抑制剂在非小细胞肺癌肝转移患者中的疗效：一项真实世界研究
Cancers (Basel). 2022 Sep 5;14(17):4333. doi: 10.3390/cancers14174333.
Zotero 插件